123 related articles for article (PubMed ID: 37992541)
1. Role of HDAC6-STAT3 in immunomodulatory pathways in Colorectal cancer cells.
Mardones C; Navarrete-Munoz C; Armijo ME; Salgado K; Rivas-Valdes F; Gonzalez-Pecchi V; Farkas C; Villagra A; Hepp MI
Mol Immunol; 2023 Dec; 164():98-111. PubMed ID: 37992541
[TBL] [Abstract][Full Text] [Related]
2. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Keremu A; Aimaiti A; Liang Z; Zou X
Cancer Chemother Pharmacol; 2019 Feb; 83(2):255-264. PubMed ID: 30430228
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
4. Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
M L; P PV; T K; M P; E S; J P; K V W; C L; F C; S D; M SKS; M M; A K; J PI; A S; E S; J W; E M S; A V
Mol Oncol; 2016 May; 10(5):735-750. PubMed ID: 26775640
[TBL] [Abstract][Full Text] [Related]
5. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy.
Wen Y; Ye S; Li Z; Zhang X; Liu C; Wu Y; Zheng R; Xu C; Tian J; Shu L; Yan Q; Ai F; Ma J
Cancer Immunol Immunother; 2024 Jan; 73(1):7. PubMed ID: 38231305
[TBL] [Abstract][Full Text] [Related]
6. S100A14: A novel negative regulator of cancer stemness and immune evasion by inhibiting STAT3-mediated programmed death-ligand 1 expression in colorectal cancer.
Min HY; Cho J; Sim JY; Boo HJ; Lee JS; Lee SB; Lee YJ; Kim SJ; Kim KP; Park IJ; Hong SM; Zhang XL; Zhang ZG; Park RW; Lee HY
Clin Transl Med; 2022 Jul; 12(7):e986. PubMed ID: 35858011
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Li A; Chen P; Leng Y; Kang J
Oncogene; 2018 Nov; 37(45):5952-5966. PubMed ID: 29980788
[TBL] [Abstract][Full Text] [Related]
8. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C
Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670
[TBL] [Abstract][Full Text] [Related]
9. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs.
Cheng F; Lienlaf M; Wang HW; Perez-Villarroel P; Lee C; Woan K; Rock-Klotz J; Sahakian E; Woods D; Pinilla-Ibarz J; Kalin J; Tao J; Hancock W; Kozikowski A; Seto E; Villagra A; Sotomayor EM
J Immunol; 2014 Sep; 193(6):2850-62. PubMed ID: 25108026
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
11. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
12. Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer.
Vuletić A; Mirjačić Martinović K; Spasić J
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258065
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Shi Y; Ni J; Tao M; Ma X; Wang Y; Zang X; Hu Y; Qiu A; Zhuang S; Liu N
Ren Fail; 2020 Nov; 42(1):890-901. PubMed ID: 32862739
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Shin HS; Choi J; Lee J; Lee SY
Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693
[TBL] [Abstract][Full Text] [Related]
15. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth.
De Simone V; Franzè E; Ronchetti G; Colantoni A; Fantini MC; Di Fusco D; Sica GS; Sileri P; MacDonald TT; Pallone F; Monteleone G; Stolfi C
Oncogene; 2015 Jul; 34(27):3493-503. PubMed ID: 25174402
[TBL] [Abstract][Full Text] [Related]
16. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
17. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer.
Zuo HX; Jin Y; Wang Z; Li MY; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin CH; Xu GH; Piao LX; Ma J; Jin X
J Ethnopharmacol; 2020 Jul; 257():112835. PubMed ID: 32278762
[TBL] [Abstract][Full Text] [Related]
18. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells.
Liu S; Sun X; Wang M; Hou Y; Zhan Y; Jiang Y; Liu Z; Cao X; Chen P; Liu Z; Chen X; Tao Y; Xu C; Mao J; Cheng C; Li C; Hu Y; Wang L; Chin YE; Shi Y; Siebenlist U; Zhang X
Gastroenterology; 2014 Oct; 147(4):847-859.e11. PubMed ID: 24931456
[TBL] [Abstract][Full Text] [Related]
19. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
20. STAT3 inhibition reduced PD-L1 expression and enhanced antitumor immune responses.
Jahangiri A; Dadmanesh M; Ghorban K
J Cell Physiol; 2020 Dec; 235(12):9457-9463. PubMed ID: 32401358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
